COMPOUNDS HAVING INHIBITORY ACTIVITY RELATIVELY TO PDE9A AND THEIR PHARMACEUTICAL USE Russian patent published in 2023 - IPC C07D487/04 A61K31/519 A61P7/00 A61P9/04 A61P25/18 A61P25/28 

FIELD: medicine.

SUBSTANCE: invention relates to a compound represented by the chemical formula 1 or to its pharmaceutically acceptable salt, where A¹ is NH or N-C_1-2-alkyl, A² is H, linear or branched C_1-5-alkyl, or phenyl, X is a substitute selected from a group consisting of -H, a halogen atom, -SR¹, linear or branched C_1-10-alkyl unsubstituted or substituted with one or two halogen atoms, linear or branched C_1-10-alkoxy group unsubstituted or substituted with one or two halogen atoms, and C_6-10-aryl unsubstituted or substituted with one or two halogen atoms, or linear or branched C_1-10 alkyl, Y is a substitute selected from a group consisting of linear or branched C_1-10-alkyl unsubstituted or substituted with one or two halogen atoms, C_3-10-cycloalkyl unsubstituted or substituted with one or two halogen atoms, 6-10-element heterocycloalkyl containing heteroatom of O or S, and C_6-10-aryl unsubstituted or substituted with one or two halogen atoms, R₁ is a substitute selected from a group consisting of linear or branched C_1-10 alkyl unsubstituted or substituted with one or two halogen atoms and C_1-2-alkyl-C_6-10-aryl unsubstituted or substituted with one or two halogen atoms, or linear or branched C_1-10 alkyl, provided that the compound is not N-(5-methyl-1,3,4-thiadiazol-2-yl)-2-((4-oxo-1-phenyl-4,5-dihydro-1H-pyrazol[3,4-d]pyrimidine-6-yl)thio)acetamide. The invention also relates to a pharmaceutical composition for the treatment or prevention of a disease related to phosphodiesterase 9A based on the specified compound.

EFFECT: new compounds and a pharmaceutical composition based on them are obtained, which can be used in medicine for the treatment of neurological or mental diseases, as well as heart failure.

[Chemical formula 1]

8 cl, 2 tbl, 48 ex